• 1. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 2. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 3. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 4. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 5. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339

1-Methyl-6-(1-methylethyl)-1H-indole-2-carboxylic Acid (CAS No. 1240579-11-6): An Overview

1-Methyl-6-(1-methylethyl)-1H-indole-2-carboxylic Acid (CAS No. 1240579-11-6) is a versatile organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its unique indole scaffold, exhibits a range of biological activities that make it a valuable candidate for drug development. In this comprehensive overview, we will delve into the chemical properties, synthesis methods, biological activities, and potential applications of 1-Methyl-6-(1-methylethyl)-1H-indole-2-carboxylic Acid.

The chemical structure of 1-Methyl-6-(1-methylethyl)-1H-indole-2-carboxylic Acid is defined by its indole core, which is a fundamental building block in many biologically active molecules. The presence of a methyl group at the 1-position and an isopropyl group at the 6-position imparts unique structural features that influence its chemical and biological properties. The carboxylic acid moiety at the 2-position further enhances its reactivity and functional versatility.

In terms of synthesis, several methods have been reported for the preparation of 1-Methyl-6-(1-methylethyl)-1H-indole-2-carboxylic Acid. One common approach involves the condensation of an appropriate indole derivative with a carboxylic acid or ester, followed by functional group manipulations to achieve the desired substitution pattern. Recent advancements in synthetic chemistry have also led to more efficient and environmentally friendly routes, such as catalytic methods and microwave-assisted synthesis.

The biological activities of 1-Methyl-6-(1-methylethyl)-1H-indole-2-carboxylic Acid have been extensively studied in various contexts. One notable area of research is its potential as an anti-inflammatory agent. Studies have shown that this compound can effectively inhibit the production of pro-inflammatory cytokines, such as TNF-α and IL-6, in both in vitro and in vivo models. This property makes it a promising candidate for the treatment of inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease.

Beyond its anti-inflammatory effects, 1-Methyl-6-(1-methylethyl)-1H-indole-2-carboxylic Acid has also demonstrated antitumor activity. Research has indicated that it can induce apoptosis in cancer cells by modulating key signaling pathways, such as the PI3K/AKT and MAPK pathways. These findings suggest that this compound could be developed into a novel therapeutic agent for cancer treatment.

In addition to its direct biological effects, 1-Methyl-6-(1-methylethyl)-1H-indole-2-carboxylic Acid has been explored as a scaffold for the design of more potent and selective analogs. Through structure-activity relationship (SAR) studies, researchers have identified key structural modifications that enhance the compound's pharmacological properties. For example, substituting the carboxylic acid group with other functional groups has led to compounds with improved solubility and bioavailability.

The pharmacokinetic properties of 1-Methyl-6-(1-methylethyl)-1H-indole-2-carboxylic Acid are also an important consideration for its therapeutic potential. Studies have shown that this compound exhibits favorable absorption, distribution, metabolism, and excretion (ADME) profiles. Its oral bioavailability is relatively high, and it shows good stability in plasma and tissues. These characteristics make it suitable for both oral and parenteral administration.

Clinical trials are currently underway to evaluate the safety and efficacy of 1-Methyl-6-(1-methylethyl)-1H-indole-2-carboxylic Acid in various disease models. Preliminary results from phase I trials have demonstrated that this compound is well-tolerated by patients and shows promising therapeutic effects. Further clinical studies are needed to fully elucidate its potential as a therapeutic agent.

In conclusion, 1-Methyl-6-(1-methylethyl)-1H-indole-2-carboxylic Acid (CAS No. 1240579-11-6) is a multifaceted compound with significant potential in medicinal chemistry and pharmaceutical research. Its unique chemical structure, coupled with its diverse biological activities, makes it a valuable candidate for drug development. Ongoing research continues to uncover new insights into its mechanisms of action and therapeutic applications, paving the way for future advancements in healthcare.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)